BTIG Research Raises Liquidia (NASDAQ:LQDA) Price Target to $59.00

BTIG Research Raises Liquidia (NASDAQ:LQDA) Price Target to $59.00

BTIG Research increased their price target on Liquidia from $50.00 to $59.00 and gave the company a "buy" rating in a report on Monday.

Liquidia Corporation (LQDA) Q1 2026 Earnings Call Transcript

Operator Good morning, and welcome to Liquidia Corporation First Quarter 2026 Financial Results and Corporate Update Conference Call. My name is Jonathan, and I will be your operator today. [Operator Instructions] Please note that today’s call is being recorded. And now I’d like to turn the call over to Jason Adair, Liquidia’s Chief Business Officer. You may proceed. Jason AdairChief Business Officer Thank you, and good morning, everyone. It’s …

Liquidia (LQDA) Stock Soars 25% on Explosive YUTREPIA Sales and Record Q1 Profit

NEW YORK — Shares of Liquidia Corporation (NASDAQ: LQDA) surged more than 25% in morning trading Monday to $48.54 as investors cheered the biopharmaceutical company's transformative first-quarter 2026 results, driven by the blockbuster commercial launch of its pulmonary hypertension drug YUTREPIA.